Biosimilar insulin interchangeability — the FDA designation enabling pharmacists to substitute biosimilar insulins for reference products without prescriber consultation, dramatically expanding patient access while reducing costs — represents the fastest-transforming regulatory and commercial dynamic in the global recombinant insulin landscape, with the Human Recombinant...